Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

53.85
-0.2600-0.48%
Volume:69.65K
Turnover:3.75M
Market Cap:1.59B
PE:-59.52
High:54.57
Open:54.28
Low:53.22
Close:54.11
52wk High:73.30
52wk Low:17.11
Shares:29.61M
Float Shares:21.05M
Volume Ratio:0.61
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9047
EPS(LYR):-0.4601
ROE:-114.55%
ROA:6.78%
PB:125.08
PE(LYR):-117.04

Loading ...

AnaptysBio announces $100M share repurchase program

TIPRANKS
·
Mar 27

AnaptysBio; First Tracks Bio private placement raises $80 million at $13.81 per share

Reuters
·
Mar 27

BRIEF-Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update

Reuters
·
Mar 27

BRIEF-Anaptys Board Of Directors Approves Spin-Off Of First Tracks Biotherapeutics

Reuters
·
Mar 27

BRIEF-First Tracks Biotherapeutics, The Planned Spin-Off Of Anaptys, Secures Commitments Of $145 Million In Private Placement

Reuters
·
Mar 27

AnaptysBio authorizes $100.0 million stock repurchase plan; program expires Dec. 31, 2026

Reuters
·
Mar 27

AnaptysBio Inc: Search Initiated for a CFO for Anaptys Post the Spin-off of First Tracks Bio

THOMSON REUTERS
·
Mar 27

AnaptysBio Inc: Daniel Faga Will Continue as CEO of Anaptys Post the Spin-off of First Tracks Bio

THOMSON REUTERS
·
Mar 27

AnaptysBio Inc: Post Spin-off Anticipate Paydown of Remaining Non-Recourse Debt Monetization to Sagard by the End of Q2 2027

THOMSON REUTERS
·
Mar 27

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

THOMSON REUTERS
·
Mar 27

AnaptysBio Inc - to Spin-off Biopharma Operations Into First Tracks Biotherapeutics on April 20, 2026

THOMSON REUTERS
·
Mar 27

AnaptysBio Inc - Ajim Tamboli Expected to Be Appointed CFO of First Tracks Bio

THOMSON REUTERS
·
Mar 27

AnaptysBio Inc - First Tracks Bio 'When-Issued' Nasdaq Trading Under the Symbol “Trax”, Expected to Begin April 6, 2026

THOMSON REUTERS
·
Mar 27

AnaptysBio Inc - First Tracks Bio to Launch With Two-Year Cash Runway

THOMSON REUTERS
·
Mar 27

First Tracks Biotherapeutics, the Planned Spin-off of Anaptys, Secures Commitments of $145 Million in Private Placement

THOMSON REUTERS
·
Mar 27